Listar Enfermidades endocrinas, nutricionais e metabólicas por autor "Venegas, Eva"
Mostrando ítems 1-4 de 4
-
Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly
Bernabéu, Ignacio; Fajardo, Carmen; Marazuela, Mónica; Cordido, Fernando; Venegas, Eva; Pablos Velasco, Pedro de; Piedrola Maroto, Gonzalo; Olvera Márquez, María del Pilar; Pavón de Paz, Isabel; Carvalho, Davide; Romero, Carmen; De la Cruz, Guillermo; Álvarez Escolá, Cristina (Springer, 2020-07-28)[Abstract] Purpose. Recent data indicate that extended dosing intervals (EDIs) with lanreotide autogel 120 mg are effective and well-received among patients with acromegaly who have achieved biochemical control with monthly ... -
Observational, multicentre study to evaluate the effectiveness in routine clinical practice of Lanreotide Autogel 120 mg at extended dosing intervals (>4 weeks) for the treatment of acromegaly: SOMACROL study
Álvarez Escolá, Cristina; Fajardo, Carmen; Marazuela, Mónica; Cordido, Fernando; Venegas, Eva; Pablos Velasco, Pedro de; Piedrola Maroto, Gonzalo; Olvera Márquez, María del Pilar; Pavón de Paz, Isabel; Carvalho, Davide; Romero, Carmen; De la Cruz, Guillermo; Bernabéu, Ignacio (Bioscientifica, 2018-05) -
Treatment adherence to pegvisomant (somavert®) in Spain: PEGASO study
Cámara, Rosa; Venegas, Eva; García-Arnés, Juan Antonio; Cordido, Fernando; Aller, J.; Martín, Víctor; Sánchez-Cenizo, Laura; Mir, Nuria (Oxford, 2017) -
Treatment adherence to pegvisomant in patients with acromegaly in Spain: PEGASO study
Cámara, Rosa; Venegas, Eva; García-Arnés, Juan Antonio; Cordido, Fernando; Aller, J.; Samaniego, M. Luz; Mir, Nuria; Sánchez-Cenizo, Laura (Springer, 2019-02-13)[Abstract] PURPOSE: The burden of chronic daily subcutaneous administration of pegvisomant on adherence has not been previously studied. This study was aimed to determine the adherence to pegvisomant treatment in acromegaly ...